1α,25-Dihydroxyvitamin D3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells

Oncogene

Volumn 24, Issue 43, 2005, Pages 6533-6544

  Fernandez Garcia, Nuria Isabel ^a,b   Palmer, Hector G ^c   Garcia, Marta ^d   Gonzalez Martin, Alicia ^a,b   Del Rio, Marcela ^d   Barettino, Domingo ^e   Volpert, Olga ^f   Muñoz, Alberto ^a   Jimenez, Benilde ^a,b  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c National Cancer Research Institute   (United Kingdom)

^d CIEMAT   (Spain)

^e INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

1 ,25(OH)2D3; Angiogenesis; Colon carcinoma; E cadherin; Id

Indexed keywords

ANGIOGENIC FACTOR; BETA CATENIN; CALCITRIOL; INHIBITOR OF DIFFERENTIATION 1; INHIBITOR OF DIFFERENTIATION 2; NUCLEIC ACID BINDING PROTEIN; RNA; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; CADHERIN; CATNB PROTEIN, MOUSE; CTNNB1 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; DIHYDROXY VITAMIN D3; DIHYDROXY-VITAMIN D3; DNA BINDING PROTEIN; DRUG DERIVATIVE; ID1 PROTEIN, HUMAN; ID2 PROTEIN, HUMAN; IDB1 PROTEIN, MOUSE; IDB2 PROTEIN, MOUSE; REPRESSOR PROTEIN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; VITAMIN D;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; GAP JUNCTION; GENE CONTROL; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MULTIGENE FAMILY; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; TRANSCRIPTION REGULATION; ANIMAL; C57BL MOUSE; CARCINOMA; CELL CULTURE; COLON TUMOR; DRUG EFFECT; GENETICS; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANIMALS; BETA CATENIN; CADHERINS; CARCINOMA; CELL PROLIFERATION; COLONIC NEOPLASMS; CYTOSKELETAL PROTEINS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; INHIBITOR OF DIFFERENTIATION PROTEIN 2; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS (GENETICS); REPRESSOR PROTEINS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; VITAMIN D;

EID: 26944461665     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1208801     Document Type: Article

References (48)

1. Behrens J. (2000). Ann. N. Y. Acad. Sci., 910, 21-33; discussion 33-35.
2. Benezra R, Rafii S and Lyden D. (2001). Oncogene, 20, 8334-8341.
3. Bernardi RJ, Johnson CS, Modzelewski RA and Trump DL. (2002). Endocrinology, 143, 2508-2514.
4. Chomczynski P and Sacchi N. (1987). Anal. Biochem., 162, 156-159.
5. Church GM and Gilbert W. (1984). Proc. Natl. Acad. Sci. USA, 81, 1991-1995.
6. Dalhoff K, Dancey J, Astrup L, Skovsgaard T, Hamberg KJ, Lofts FJ, Rosmorduc O, Erlinger S, Bach Hansen J, Steward WP, Skov T, Burcharth F and Evans TR. (2003). Br. J. Cancer, 89, 252-257.
7. Dameron KM, Volpert OV, Tainsky MA and Bouck N. (1994). Science, 265, 1582-1584.
8. Diaz GD, Paraskeva C, Thomas MG, Binderup L and Hague A. (2000). Cancer Res., 60, 2304-2312.
9. Evans SR, Shchepotin EI, Young H, Rochon J, Uskokovic M and Shchepotin IB. (2000). Int. J. Oncol., 16, 1249-1254.
10. Ezura Y, Tournay O, Nifuji A and Noda M. (1997). J. Biol. Chem., 272, 29865-29872.
11. Gross C, Stamey T, Hancock S and Feldman D. (1998). J. Urol., 159, 2035-2039; discussion 2039-2040.
12. Gulliford T, English J, Colston KW, Menday P, Moller S and Coombes RC. (1998). Br. J. Cancer, 78, 6-13.
13. Gumireddy K, Ikegaki N, Phillips PC, Sutton LN and Reddy CD. (2003). Biochem. Pharmacol., 65, 1943-1955.
14. Guyton KZ, Kensler TW and Posner GH. (2001). Annu. Rev. Pharmacol. Toxicol., 41, 421-442.
15. Halline AG, Davidson NO, Skarosi SF, Sitrin MD, Tietze C, Alpers DH and Brasitus TA. (1994). Endocrinology, 134, 1710-1717.
16. Hewitt RE, McMarlin A, Kleiner D, Wersto R, Martin P, Tsokos M, Stamp GW, Stetler-Stevenson WG and Tsoskas M. (2000). J. Pathol., 192, 446-454.
17. Iseki K, Tatsuta M, Uehara H, Iishi H, Yano H, Sakai N and Ishiguro S. (1999). Int. J. Cancer, 81, 730-733.
18. Israel MA, Hernandez MC, Florio M, Andres-Barquin PJ, Mantani A, Carter JH and Julin CM. (1999). Cancer Res., 59, 1726s-1730s.
19. Jensen SS, Madsen MW, Lukas J, Binderup L and Bartek J. (2001). Mol. Endocrinol., 15, 1370-1380.
20. Koli K and Keski-Oja J. (2000). Cell Growth Differ., 11, 221-229.
21. Lasorella A, Boldrini R, Dominici C, Donfrancesco A, Yokota Y, Inserra A and Iavarone A. (2002). Cancer Res., 62, 301-306.
22. Lasorella A, Iavarone A and Israel MA. (1996). Mol. Cell. Biol., 16, 2570-2578.
23. Lasorella A, Noseda M, Beyna M, Yokota Y and Iavarone A. (2000). Nature, 407, 592-598.
24. Lasorella A, Uo T and Iavarone A. (2001). Oncogene, 20, 8326-8333.
25. Leibovitz A, Stinson JC, McCombs III WB, McCoy CE, Mazur KC and Mabry ND. (1976). Cancer Res., 36, 4562-4569.
26. Liu Y, Encinas M, Comella JX, Aldea M and Gallego C. (2004). Mol. Cell. Biol., 24, 2662-2672.
27. Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O'Reilly R, Bader BL, Hynes RO, Zhuang Y, Manova K and Benezra R. (1999). Nature, 401, 670-677.
28. Mantell DJ, Owens PE, Bundred NJ, Mawer EB and Canfield AE. (2000). Circ. Res., 87, 214-220.
29. Matsumura ME, Lobe DR and McNamara CA. (2002). J. Biol. Chem., 277, 7293-7297.
30. Nehlin JO, Hara E, Kuo WL, Collins C and Campisi J. (1997). Biochem. Biophys. Res. Commun., 231, 628-634.
31. Nishii Y and Okano T. (2001). Steroids, 66, 137-146.
32. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M and Munoz A. (2001). J. Cell Biol., 154, 369-387.
33. Palmer HG, Sanchez-Carbayo M, Ordonez-Moran P, Larriba MJ, Cordon-Cardo C and Munoz A. (2003). Cancer Res., 63, 7799-7806.
34. Ramsauer M and D'Amore PA. (2002). J. Clin. Invest., 110, 1615-1617.
35. Rockman SP, Currie SA, Ciavarella M, Vincan E, Dow C, Thomas RJ and Phillips WA. (2001). J. Biol. Chem., 276, 45113-45119.
36. Ruzinova MB, Schoer RA, Gerald W, Egan JE, Pandolfi PP, Rafii S, Manova K, Mittal V and Benezra R. (2003). Cancer Cell 4, 277-289.
37. Scaglione-Sewell BA, Bissonnette M, Skarosi S, Abraham C and Brasitus TA. (2000). Endocrinology, 141, 3931-3939.
38. Schlaeppi JM, Gutzwiller S, Finkenzeller G and Fournier B. (1997). Endocr. Res., 23, 213-229.
39. Sikder HA, Devlin MK, Dunlap S, Ryu B and Alani RM. (2003). Cancer Cell, 3, 525-530.
40. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW and Trump DL. (1999). Clin. Cancer Res., 5, 1339-1345.
41. Vennstrom B and Bishop JM. (1982). Cell, 28, 135-143.
42. Verlinden L, Verstuyf A, Convents R, Marcelis S, Van Camp M and Bouillon R. (1998). Mol. Cell. Endocrinol., 142, 57-65.
43. Volpert OV, Pili R, Sikder HA, Nelius T, Zaichuk T, Morris C, Shiflett CB, Devlin MK, Conant K and Alani RM. (2002). Cancer Cell, 2, 473-483.
44. Wilson JW, Deed RW, Inoue T, Balzi M, Becciolini A, Faraoni P, Potten CS and Norton JD. (2001). Cancer Res., 61, 8803-8810.
45. Woo PL, Cercek A, Desprez PY and Firestone GL. (2000). J. Biol. Chem., 275, 28649-28658.
46. Yam CH, Fung TK and Poon RY. (2002). Cell Mol. Life Sci., 59, 1317-1326.
47. Yokota Y. (2001). Oncogene, 20, 8290-8298.
48. Zebedee Z and Hara E. (2001). Oncogene, 20, 8317-8325.